Literature DB >> 29454571

Feasibility of restorative proctocolectomy in patients with ulcerative colitis-associated lower rectal cancer: A retrospective study.

Shinnosuke Hotta1, Yoshifumi Shimada2, Mae Nakano1, Saki Yamada1, Kaoru Abe1, Hidehito Oyanagi1, Ryoma Yagi1, Yosuke Tajima1, Masato Nakano1, Hitoshi Kameyama1, Masayuki Nagahashi1, Jun Sakata1, Takashi Kobayashi1, Toshifumi Wakai1.   

Abstract

BACKGROUND/
OBJECTIVE: Restorative proctocolectomy (RP) may improve quality of life in patients with ulcerative colitis (UC)-associated lower rectal cancer to a greater extent than total proctocolectomy. However, patients with UC-associated cancer often have flat mucosal lesions that make it extremely difficult to endoscopically delineate the tumor margins. Therefore, there is a potential risk of residual tumor and local recurrence after RP in patients with UC-associated lower rectal cancer. The aim of this study was to assess the feasibility of RP in patients with UC-associated cancer of the lower rectum.
METHODS: We retrospectively identified nine patients who had undergone RP for UC-associated lower rectal cancer at the Niigata University Medical and Dental Hospital between January 2000 and December 2016. The incidence of flat mucosal cancer, distal margin status, and oncologic outcomes were evaluated in the nine patients.
RESULTS: Eight (89%) of the nine patients had flat mucosal cancer in the lower rectum. The median length of the distal margin was 22 mm (range 0-55 mm). No patient developed local or distant recurrence during follow-up. One patient had a positive distal margin. This patient underwent annual pouchoscopy, but had no local recurrence and died of pancreatic cancer 81 months after RP. The remaining eight patients were alive at the final observation. Five-year and 10-year overall survival rates in the nine patients were 100% and 66.7%, respectively.
CONCLUSION: Patients with UC-associated lower rectal cancer often have lesions of the flat mucosal type. However, RP is feasible and not necessarily contraindicated in such patients.
Copyright © 2018. Published by Elsevier Taiwan LLC.

Entities:  

Keywords:  inflammatory bowel disease; rectal cancer; restorative proctocolectomy; ulcerative colitis; ulcerative colitis-associated cancer

Mesh:

Year:  2018        PMID: 29454571     DOI: 10.1016/j.asjsur.2018.01.003

Source DB:  PubMed          Journal:  Asian J Surg        ISSN: 1015-9584            Impact factor:   2.767


  2 in total

1.  Management of Low Rectal Cancer Complicating Ulcerative Colitis: Proposal of a Treatment Algorithm.

Authors:  Bruno Sensi; Giulia Bagaglini; Vittoria Bellato; Daniele Cerbo; Andrea Martina Guida; Jim Khan; Yves Panis; Luca Savino; Leandro Siragusa; Giuseppe S Sica
Journal:  Cancers (Basel)       Date:  2021-05-13       Impact factor: 6.639

2.  HLJ2 Effectively Ameliorates Colitis-Associated Cancer via Inhibition of NF-κB and Epithelial-Mesenchymal Transition.

Authors:  Huachen Song; Xiaonan Tang; Xiang Li; Yufei Wang; Anjun Deng; Wenjie Wang; Haijing Zhang; Hailin Qin; LianQiu Wu
Journal:  Drug Des Devel Ther       Date:  2020-10-15       Impact factor: 4.162

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.